Trevi Therapeutics (TRVI) EBIT (2018 - 2026)
Trevi Therapeutics' (TRVI) quarterly EBIT came in at -$13.0 million in Q1 2026, down 27.61% year-on-year from -$18.0 million in Q1 2025, and down 27.22% quarter-over-quarter from -$10.2 million in Q4 2025.
Trevi Therapeutics (TRVI) EBIT (2018 - 2026) Analysis & Trends
Trevi Therapeutics' EBIT history runs 9 years deep, the most recent figure standing at -$13.0 million for Q1 2026.
- On a quarterly basis, EBIT fell 27.61% year-over-year to -$13.0 million in Q1 2026; TTM through Mar 2026 was -$50.9 million, a 2.11% decrease from a year earlier, with the FY2025 full-year figure at -$49.3 million, up 4.26% from the prior year.
- EBIT retreated to -$13.0 million in Q1 2026 per TRVI's latest filing, from -$10.2 million in the prior quarter.
- Across five years, EBIT topped out at -$6.7 million in Q4 2022 and bottomed at -$14.1 million in Q3 2024.
- The 5-year median for EBIT is -$10.2 million (2025), against an average of -$10.4 million.
- Across the five-year window, EBIT rose 19.53% in 2022 and plunged 58.54% in 2024, its largest moves.
- Year by year, EBIT stood at -$6.7 million in 2022, then tumbled by 34.19% to -$8.9 million in 2023, then tumbled by 37.05% to -$12.2 million in 2024, then gained by 16.52% to -$10.2 million in 2025, then retreated by 27.22% to -$13.0 million in 2026.
- Per Business Quant, the three latest TRVI EBIT figures stand at -$13.0 million (Q1 2026), -$10.2 million (Q4 2025), and -$13.9 million (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -27.75 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -15.76 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 249.90 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.14 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 642.90 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | -32.68 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 394.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -445.22 Mn |
| 10 | Trevi Therapeutics | 2.54 Bn | 2.54 Bn | - | -13.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -13.00 Mn |
| Dec 31, 2025 | -10.22 Mn |
| Sep 30, 2025 | -13.92 Mn |
| Jun 30, 2025 | -13.72 Mn |
| Mar 31, 2025 | -10.19 Mn |
| Dec 31, 2024 | -12.24 Mn |
| Sep 30, 2024 | -14.09 Mn |
| Jun 30, 2024 | -13.29 Mn |
| Mar 31, 2024 | -11.91 Mn |
| Dec 31, 2023 | -8.93 Mn |
| Sep 30, 2023 | -9.05 Mn |
| Jun 30, 2023 | -8.38 Mn |
| Mar 31, 2023 | -7.56 Mn |
| Dec 31, 2022 | -6.66 Mn |
| Sep 30, 2022 | -8.41 Mn |
| Jun 30, 2022 | -7.82 Mn |
| Mar 31, 2022 | -7.03 Mn |
| Dec 31, 2021 | -8.27 Mn |
| Sep 30, 2021 | -6.95 Mn |
| Jun 30, 2021 | -9.17 Mn |